

SPECTRUM PHARMACEUTICALS INC

Form 8-K

June 03, 2003

Table of Contents

**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(D) OF THE  
SECURITIES AND EXCHANGE ACT OF 1934**

June 3, 2003

Date of Report (Date of earliest event reported)

**SPECTRUM PHARMACEUTICALS, INC.**

(Exact name of registrant as specified in its charter)

**Delaware**

(State or other Jurisdiction  
of Incorporation)

**000-28782**

(Commission File Number)

**93-0979187**

(IRS Employer  
Identification Number)

**157 Technology Drive  
Irvine, California**

(Address of principal executive offices)

**92618**

(Zip Code)

**(949) 788-6700**

(Registrant's telephone number, including area code)

N/A

(Former Name or Former Address, if Changed Since Last Report)

---

**TABLE OF CONTENTS**

Item 5. Other Events

Item 7. Exhibits

SIGNATURES

EXHIBIT INDEX

EXHIBIT 99.1

---

**Table of Contents**

**Item 5. Other Events**

On June 3, 2003, Spectrum Pharmaceuticals, Inc. (the Company) announced the presentation of positive clinical data on its lead compound, satraplatin, at the Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago. The study, entitled, "Randomized phase III trial of a new oral platinum, satraplatin (JM-216) plus prednisone or prednisone alone in patients with hormone refractory prostate cancer, (Abstract #1586) was presented by Cora N. Sternberg, M.D., FACP, Chief of the Department of Medical Oncology at the San Camillo and Forlanini Hospitals, Rome, Italy and Head of the Genitourinary Tract Group for the European Organization for the Research and Treatment of Cancer (EORTC). The study results demonstrated statistically significant superiority of the satraplatin arm ( $p=0.023$ ) in time to disease progression, with doubling of progression-free survival.

A copy of the Company's press release is attached hereto as Exhibit 99.1 and is incorporated herein by this reference.

**Item 7. Exhibits**

**Exhibits:**

99.1 Press release dated June 3, 2003.

**Table of Contents**

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SPECTRUM PHARMACEUTICALS, INC.

Date: June 3, 2003

By: /s/ Michael McManus \_\_\_\_\_

Name: Michael McManus

Title: Controller

**Table of Contents**

**EXHIBIT INDEX**

**Exhibits:**

99.1 Press release dated June 3, 2003.